Jeffrey Lande

Title: The Innovations of Jeffrey Lande

Introduction

Jeffrey Lande is a notable inventor based in Minneapolis, MN (US). He has made significant contributions to the field of cardiac health through his innovative patent. His work focuses on methods and compositions that aid in the identification and selection of therapies for Sudden Cardiac Death (SCD), Sudden Cardiac Arrest (SCA), and related conditions.

Latest Patents

Lande holds a patent for "Methods and compositions for SCD, CRT, CRT-D, or SCA therapy identification and/or selection." This patent encompasses compositions, polynucleotides, probes, kits, methods, computer systems, treatment methods, and genetic markers that are useful for assessing the risk of SCD, SCA, Ventricular Arrhythmia (VA), or Heart Failure (HF). The invention provides a means for selecting patients who can be treated with an Implantable Cardioverter Defibrillator (ICD) or Cardiac Resynchronization Therapy Defibrillator (CRT-D) based on the presence of specific Single Nucleotide Polymorphisms (SNPs) associated with these conditions. Additionally, it indicates potential treatment options with certain drugs, such as beta-blockers.

Career Highlights

Jeffrey Lande is currently associated with Medtronic, Inc., a leading company in medical technology. His work at Medtronic has allowed him to contribute to advancements in cardiac care and patient safety.

Collaborations

Lande has collaborated with notable colleagues, including Orhan Soykan and Tara Nahey, to further enhance the impact of his innovations in the medical field.

Conclusion

Jeffrey Lande's contributions to cardiac health through his patent demonstrate his commitment to improving patient outcomes. His innovative approaches continue to influence the field of cardiology and enhance treatment options for patients at risk of serious cardiac events.